The combination of HAIC, lenvatinib, and PD-1 inhibitors may result in synergistic anti-tumor effects, as each therapeutic approach targets different pathways involved in tumor growth and survival, and concurrent use of multiple treatments can overcome drug resistance which often limits clinical efficacy of single-agent therapies (19–21). Here, PDCD1 is linked to neoplasm.